Skip to main content
Study of 155 adult patients (PsA 61/AS 94) looked at labs & CV risk factors; found IL-18 elevated in peripheral PsA

Dr. John Cush RheumNow

4 years 6 months ago
Study of 155 adult patients (PsA 61/AS 94) looked at labs & CV risk factors; found IL-18 elevated in peripheral PsA more than axial PsA & AS. Elevations were higher in PsA pts w/ ischemic heart disease correlated w/ atherogenic index & TG levels https://t.co/PQ3fBi8Qdo https://t.co/mewrcwhi4o
Another Kind of COVID Discussion

Another kind of COVID (vaccination) discussion - kindness and respect for the patient

Dr. John Cush RheumNow

4 years 6 months ago
Another Kind of COVID Discussion Another kind of COVID (vaccination) discussion - kindness and respect for the patient QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/XkUkqQ1Vli https://t.co/lrPd6jBMjt
ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis

The ACR has updated its clinical guidelines

Dr. John Cush RheumNow

4 years 6 months ago
ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis The ACR has updated its clinical guidelines for the management of JIA, with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA. https://t.co/eKv8qubl1v https://t.co/xLBMccCYex
Gout is common but disproportionately affects certain groups (e.g., the elderly, Pacific Islander, Blacks). Ethnic links to gouts were also shown to be linked to modifiable behavioral factors and such information maybe useful in managing gout patients.
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at

Dr. John Cush RheumNow

4 years 6 months ago
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0
Undifferentiated arthritis (UA) is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach. While there are criteria for UA, it is largely a diagnosis of exclusion. Moreover, there are few well controlled trials on DMARD efficacy in UA are absent.
Rheumatoid Arthritis and Eosinophilia

Considerations when eosinophilia is seen in RA patients.

QD Clinic is sponsored

Dr. John Cush RheumNow

4 years 6 months ago
Rheumatoid Arthritis and Eosinophilia Considerations when eosinophilia is seen in RA patients. QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/2FszCiTLgf https://t.co/07uZT2heW3
CORVITAS RA registry shows poor biologic responses in Severe obesity (BMI >35) & underweight (<18.5) w/ no dif

Dr. John Cush RheumNow

4 years 6 months ago
CORVITAS RA registry shows poor biologic responses in Severe obesity (BMI >35) & underweight (<18.5) w/ no diff between 2891 TNFi vs 3010 non-TNFi users. Severe obesity lower odds of LDA, MCID, CDAI ~10-20% UnderWt ~50-70% https://t.co/iMvlyo4UKx https://t.co/JTQ6aRVTpH
ICYMI: Spondyloarthritis in Early Crohn's Disease

Analysis of a German Crohn's disease cohort finds that in patients wi

Dr. John Cush RheumNow

4 years 6 months ago
ICYMI: Spondyloarthritis in Early Crohn's Disease Analysis of a German Crohn's disease cohort finds that in patients with early CD, SpA was present in nearly one out of five patients and was associated with HLA-B27 positivity and a highly active CD. https://t.co/ExAHSCw5v2 https://t.co/UDZHbg9ySY
×